Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $29.27 and last traded at $28.46, with a volume of 89984 shares trading hands. The stock had previously closed at $31.49.
Analyst Ratings Changes
AMPH has been the subject of several analyst reports. Piper Sandler cut Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, Amphastar Pharmaceuticals has an average rating of "Hold" and a consensus price target of $50.33.
Check Out Our Latest Report on AMPH
Amphastar Pharmaceuticals Trading Up 0.4 %
The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a 50 day moving average of $34.50 and a two-hundred day moving average of $42.44. The stock has a market cap of $1.33 billion, a PE ratio of 9.21, a price-to-earnings-growth ratio of 2.19 and a beta of 0.81.
Insider Activity at Amphastar Pharmaceuticals
In related news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now owns 30,471 shares in the company, valued at $1,333,715.67. The trade was a 24.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the transaction, the executive vice president now owns 118,469 shares of the company's stock, valued at approximately $5,262,392.98. This represents a 5.58 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
Several large investors have recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after buying an additional 1,347,775 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after buying an additional 105,288 shares in the last quarter. Boston Trust Walden Corp increased its stake in Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock worth $36,347,000 after buying an additional 439,281 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Amphastar Pharmaceuticals by 1.5% in the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock valued at $44,674,000 after purchasing an additional 14,015 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Amphastar Pharmaceuticals by 5.1% in the fourth quarter. Northern Trust Corp now owns 613,170 shares of the company's stock valued at $22,767,000 after purchasing an additional 29,808 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Read More
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
